Taken together, our study demonstrates that modulation of ERRα promotes metabolic vulnerabilities that can be exploited therapeutically and supports inhibition of ERRα as an adjuvant therapy in advanced HER2-positive breast cancer. This evidence concerns the gene ESRRA and breast carcinoma.